Reliv’ International (OTCMKTS:RELV) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head Review

Reliv’ International (OTCMKTS:RELV) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Reliv’ International and Zevra Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv’ International	0	0	0	0	0.00
Zevra Therapeutics	0	2	9	0	2.82

Zevra Therapeutics has a consensus target price of $27.14, suggesting a potential upside of 139.78%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Reliv’ International.

Volatility and Risk

Reliv’ International has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Valuation & Earnings

This table compares Reliv’ International and Zevra Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv’ International	$35.06 million	0.09	-$440,000.00	($0.09)	-20.33
Zevra Therapeutics	$106.47 million	6.31	$83.23 million	$0.92	12.30

Zevra Therapeutics has higher revenue and earnings than Reliv’ International. Reliv’ International is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reliv’ International and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reliv’ International	-0.61%	-1.89%	-1.31%
Zevra Therapeutics	42.82%	54.54%	34.15%

Insider and Institutional Ownership

7.7% of Reliv’ International shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 30.0% of Reliv’ International shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Zevra Therapeutics beats Reliv’ International on 13 of the 14 factors compared between the two stocks.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.